Arrowhead Research ARWR Business Segments — Discovery costs

Similar metrics at other companies

EXELReportable Segment — Drug discovery

$19.48M+6.7%

LLYEarly-stage — R&D

$1.27B+27.9%

VRTXPharmaceuticals — Research expenses

$205M-0.5%

AMGNReportable Segment — R&D

$1.72B+15.7%

BBIOReportable Segment Aggregation Before Other Operating — Research And Development Expense

$111.23M-3.0%

KRYSReportable Segment — R&D

$15.33M+7.5%

Questions, answered.

What is Arrowhead Research's business segments — discovery costs?

Arrowhead Research (ARWR) reported business segments — discovery costs of $18.5M in Q1 2026.

How has Arrowhead Research's business segments — discovery costs changed year-over-year?

Arrowhead Research's business segments — discovery costs increased by 24.9% year-over-year, from $14.81M to $18.5M.

What does business segments — discovery costs mean?

Costs associated with early-stage research and identification of new drug targets.

How do you interpret business segments — discovery costs?

Higher spending indicates a robust focus on innovation and future pipeline growth, whereas lower spending may suggest a shift toward focusing on existing clinical-stage assets.

How does business segments — discovery costs compare across companies?

Comparable to 'Pre-clinical Research Expense' or 'Discovery Phase R&D' at other pharmaceutical companies.